Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607438 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
A Phase 2 study, sponsored by Veeda Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00607438 is a Phase 2 study that was terminated before completion, run by Veeda Oncology. The registered enrollment target is 16 participants.
The verdict
NCT00607438, a Phase 2 study, was terminated before completion, sponsored by Veeda Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Interventions
- DRUG Sorafenib (Nexavar)
- DRUG Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607438
The ClinicalTrials.gov registry entry for NCT00607438 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veeda Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (Nexavar) is the first listed.
NCT00607438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607438 about?
NCT00607438 is a clinical study titled "A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer". This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuous...
What is the current status of trial NCT00607438?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00607438?
The interventions under investigation include: Sorafenib (Nexavar) (DRUG), Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane) (DRUG).
Who is sponsoring clinical trial NCT00607438?
This trial is sponsored by Veeda Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.